Literature DB >> 17049816

RBANS neuropsychological profiles within schizophrenia samples recruited from non-clinical settings.

Carmel M Loughland1, Terry J Lewin, Vaughan J Carr, Jim Sheedy, Anthony W Harris.   

Abstract

BACKGROUND: This paper examines the potential impact of recruitment source differences in schizophrenia research by comparing the neuropsychological performance of volunteers from the NISAD Schizophrenia Research Register with recently published schizophrenia normative data for the Repeatable Battery for Neuropsychological Status (RBANS).
METHODS: The Register sample comprised 285 volunteers with schizophrenia or schizoaffective disorder. Their RBANS performance was compared with US data from 575 predominantly outpatient-recruited schizophrenia patients.
RESULTS: The Register sample displayed impairments in immediate and delayed memory, but near-normal language, attention and visuospatial-constructional performance (mean RBANS total score=88.72, SD=16.35). By contrast, health service-recruited schizophrenia patients displayed impairments on all RBANS scales (mean RBANS total score=70.54, SD=14.80). Within the Register sample, volunteers with low levels of current functioning had immediate and delayed memory performance comparable to the US schizophrenia sample. Gender and school completion status were also associated with different RBANS profiles.
CONCLUSIONS: These findings reinforce the notion that a severity/functioning gradient exists across schizophrenia recruitment sources, which has important implications for research design and generalizability. Memory impairments have emerged as a central feature of schizophrenia.

Entities:  

Mesh:

Year:  2006        PMID: 17049816     DOI: 10.1016/j.schres.2006.08.022

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  7 in total

1.  Cognitive and Social Functioning Correlates of Employment Among People with Severe Mental Illness.

Authors:  Javier Saavedra; Marcelino López; Sergio González; Samuel Arias; Paul Crawford
Journal:  Community Ment Health J       Date:  2015-04-21

2.  Neuropsychological Impairment in Prodromal, First-Episode, and Chronic Psychosis: Assessing RBANS Performance.

Authors:  TianHong Zhang; HuiJun Li; William S Stone; Kristen A Woodberry; Larry J Seidman; YingYing Tang; Qian Guo; KaiMing Zhuo; ZhenYing Qian; HuiRu Cui; YiKang Zhu; LiJuan Jiang; Annabelle Chow; YunXiang Tang; ChunBo Li; KaiDa Jiang; ZhengHui Yi; ZePing Xiao; JiJun Wang
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

3.  Case Report: Feasibility of a Novel Virtual Reality-Based Intervention for Patients With Schizophrenia.

Authors:  Edit Vass; Viktória Simon; Zita Fekete; Balázs Kis; Lajos Simon
Journal:  Front Psychol       Date:  2021-02-26

4.  Does Adding Social Cognitive Remediation Therapy to Neurocognitive Remediation Therapy Improve Outcomes in Young People With a Severe Mental Illness?-The Advantage Trial.

Authors:  Anthony W F Harris; Michelle Kightley; Joanna Williams; Cassandra Ma; Carlie Dodds
Journal:  Front Psychiatry       Date:  2022-03-14       Impact factor: 4.157

5.  Efficacy of metacognitive training on symptom severity, neurocognition and social cognition in patients with schizophrenia: A single-blind randomized controlled trial.

Authors:  Zita Fekete; Edit Vass; Ramóna Balajthy; Ünige Tana; Attila Csaba Nagy; Barnabás Oláh; Nóra Domján; Ildikó Szabó Kuritárné
Journal:  Scand J Psychol       Date:  2022-04-06

6.  Cigarette smoking and cognitive function in Chinese male schizophrenia: a case-control study.

Authors:  Xiang Yang Zhang; Da Chun Chen; Mei Hong Xiu; Colin N Haile; Hongqiang Sun; Lin Lu; Therese A Kosten; Thomas R Kosten
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

7.  Neurocognitive Impairment in Severe Mental Illness. Comparative study with Spanish Speaking Patients.

Authors:  Gabriel G De la Torre; Sandra Doval; David López-Sanz; Manuel García-Sedeño; Miguel A Ramallo; Macarena Bernal; Sara González-Torre
Journal:  Brain Sci       Date:  2021-03-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.